Patient characteristics. All patients had severe juvenile idiopathic arthritis–associated uveitis refractory to corticosteroids and systemic immunosuppression (n = 21 patients).
| Age, yrs (mean ± SD)* | 11.8 ± 3.6 |
| Male/female (n) | 5/16 |
| ILAR classification, n/% | |
| Persistent oligoarthritis | 7/33.3 |
| Extended oligoarthritis | 9/42.9 |
| Polyarthritis | 5/23.8 |
| ANA+, n/% | 18/85.7 |
| HLA-B27+, n/% | 2/9.5 |
| RF+, n/% | 0/0 |
| Age at JIA diagnosis, yrs (mean ± SD) | 3.7 ± 2.6 |
| Age at uveitis diagnosis, yrs (mean ± SD) | 4.3 ± 3.2 |
| Duration of uveitis, yrs (mean ± SD) | 7.5 ± 4.0 |
↵* Age at time of starting abatacept therapy. ANA: antinuclear antigen; RF: rheumatoid factor; ILAR: International League of Associations for Rheumatology; JIA: juvenile idiopathic arthritis.